The mRNA Journey: From Fragile Molecule to Programmable Medicine

In 1961, researchers at Caltech and the Pasteur Institute independently confirmed a molecule that carries genetic instructions out of the cell nucleus to the ribosomes, the cell's protein factories. They called it messenger RNA, or mRNA. It exists only briefly before breaking down, a property that decades later became both the technology's biggest engineering obstacle and, once solved, one of its safety advantages: mRNA delivers its instructions and then disappears, without altering a cell's own DNA.

Researchers wrapped mRNA that coded for a blood protein called globin inside tiny fat-based bubbles called liposomes, then delivered them into mouse cells. The cells read the instructions and built the protein. It was the first proof that mRNA didn't have to be injected naked into a cell, wrapping it in a protective fatty shell could get it there intact, an idea that became essential decades later when COVID-19 vaccines needed to survive the trip from syringe to cell.

Researchers built mRNA entirely from scratch in the lab, rather than extracting it from cells, then used positively charged fat molecules to carry it into cultured cells. The cells produced the exact protein the synthetic mRNA coded for. This decoupled the technology from biological extraction. Once mRNA could be manufactured on demand, the door opened to designing it for any protein a researcher wanted a cell to make, not just ones nature already provided.

For the first time, researchers injected mRNA directly into the muscle tissue of live mice rather than cells in a dish, and the muscle cells produced the encoded protein. It confirmed the concept could work inside a living body, not just a lab dish. But two problems stood in the way of turning this into medicine: the mRNA broke down within hours, and the immune system often reacted to it as an invader, triggering inflammation. Solving both took another 15 years.

Katalin Karikó and Drew Weissman found that swapping one of the four chemical building blocks in synthetic mRNA, called nucleosides, with a modified version let the molecule slip past the immune system's alarm sensors almost unnoticed. Unmodified synthetic mRNA had been triggering inflammation severe enough to make it impractical as a medicine. This single substitution removed that obstacle, and became the technical foundation every mRNA vaccine developed since, including the COVID-19 vaccines, was built on.

The FDA granted emergency authorization to the Pfizer-BioNTech COVID-19 vaccine after a randomized trial involving tens of thousands of participants showed roughly 95% efficacy against symptomatic infection. It was the first mRNA vaccine ever authorized for use in the general public, less than a year after the pandemic began. Moderna's mRNA vaccine followed a week later. Both relied directly on the lipid-delivery and modified-nucleoside work developed decades earlier, technology that had never been tested at this scale before.

The Nobel Committee awarded Katalin Karikó and Drew Weissman the Prize in Physiology or Medicine for the nucleoside modification discovered in 2005, the single change that let synthetic mRNA avoid triggering a damaging immune reaction. The prize came 18 years after the original discovery and three years after it had already been used in vaccines given to billions of people, an unusually direct line from a basic lab finding to a proven, widely deployed medicine.

Surgeons at Memorial Sloan Kettering Cancer Center removed pancreatic tumors from 16 patients, then sent the tissue to BioNTech, which sequenced each tumor's mutations and built a unique mRNA vaccine for that patient, designed to teach their immune system to recognize up to 20 mutated proteins specific to their own cancer. Eight of the 16 patients mounted a strong immune response. Six of those eight remained cancer-free more than three years later, reported February 19, 2025, in Nature, with immune cells still circulating in their blood years after the last dose. This is the first mRNA application in this timeline built around treating existing disease rather than preventing infection, and it requires manufacturing a distinct vaccine for every single patient, a fundamentally different production model from a mass-produced vaccine.